Literature DB >> 14719549

Pick body disease and Pick syndrome.

Toshiki Uchihara1, Kenji Ikeda, Kuniaki Tsuchiya.   

Abstract

Diagnostic criteria for Pick's disease have been criticized from many different viewpoints. This confusion is mainly derived from the ambiguity of this term 'Pick's disease' (PD), which may imply either purely histological findings, such as Pick body (PB), or a characteristic clinical syndrome that could occur even in the absence of PB. This taxonomic confusion will be circumvented by introducing the diagnostic term 'Pick body disease' to designate patients with the characteristic argyrophilic inclusions purely on histological grounds. In parallel, employment of 'Pick syndrome' to describe the time-honored clinical features may be more convenient and less confusing than PD because PD implies either the presence of PB or the clinical features, two aspects not necessarily linked to each other. Three-dimensional reconstruction of PB confirmed that tau-like immunoreactivity was accentuated at their periphery, as was recognized with the Bodian method. Preferential affinity of three-repeat tau pathology, as seen in Pick body disease, to the Bodian over the Gallyas method is distinct from the reversed affinity (the Gallyas over the Bodian method) of four-repeat tau pathology, as seen in corticobasal degeneration and in argyrophilic grains. This preference of silver staining is compatible with the mixed three- and four-repeat tau pathology, as seen in NFT of the Alzheimer's type, which are stained with both the Bodian and Gallyas staining. This will provide a practical basis on which to differentiate these disorders based on their distinctive tau species and possible relation of tau species to staining profile on these silver methods.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14719549     DOI: 10.1046/j.1440-1789.2003.00523.x

Source DB:  PubMed          Journal:  Neuropathology        ISSN: 0919-6544            Impact factor:   1.906


  9 in total

1.  Longitudinal follow-up of late-onset Alzheimer disease families.

Authors:  R M Carney; M A Slifer; P I Lin; P C Gaskell; W K Scott; C F Potocky; C M Hulette; K A Welsh-Bohmer; D E Schmechel; J M Vance; M A Pericak-Vance
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2008-07-05       Impact factor: 3.568

2.  Caspase-cleaved TAR DNA-binding protein-43 in Pick's disease.

Authors:  Troy T Rohn; Polina Kokoulina
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2009-01-01

3.  Phosphorylation of soluble tau differs in Pick's disease and Alzheimer's disease brains.

Authors:  Janet van Eersel; Mian Bi; Yazi D Ke; John R Hodges; John H Xuereb; Gillian C Gregory; Glenda M Halliday; Jürgen Götz; Jillian J Kril; Lars M Ittner
Journal:  J Neural Transm (Vienna)       Date:  2009-08-20       Impact factor: 3.575

4.  Imaging of microglia in patients with neurodegenerative disorders.

Authors:  Marios Politis; Paul Su; Paola Piccini
Journal:  Front Pharmacol       Date:  2012-05-29       Impact factor: 5.810

Review 5.  Silver diagnosis in neuropathology: principles, practice and revised interpretation.

Authors:  Toshiki Uchihara
Journal:  Acta Neuropathol       Date:  2007-03-31       Impact factor: 17.088

6.  Immunolocalization of an amino-terminal fragment of apolipoprotein E in the Pick's disease brain.

Authors:  Troy T Rohn; Ryan J Day; Lindsey W Catlin; Raquel J Brown; Alexander J Rajic; Wayne W Poon
Journal:  PLoS One       Date:  2013-12-02       Impact factor: 3.240

Review 7.  Proteostasis and Mitochondrial Role on Psychiatric and Neurodegenerative Disorders: Current Perspectives.

Authors:  Pablo Olivero; Carlo Lozano; Ramón Sotomayor-Zárate; Nicolás Meza-Concha; Marcelo Arancibia; Claudio Córdova; Wilfredo González-Arriagada; Ricardo Ramírez-Barrantes; Ivanny Marchant
Journal:  Neural Plast       Date:  2018-06-27       Impact factor: 3.599

Review 8.  Cell-to-Cell Transmission of Tau and α-Synuclein.

Authors:  Norihito Uemura; Maiko T Uemura; Kelvin C Luk; Virginia M-Y Lee; John Q Trojanowski
Journal:  Trends Mol Med       Date:  2020-05-01       Impact factor: 11.951

9.  Apolipoprotein E Fragmentation within Lewy Bodies of the Human Parkinson's Disease Brain.

Authors:  Troy T Rohn; Jacob M Mack
Journal:  Int J Neurodegener Dis       Date:  2018-02-23
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.